BioSpace News Archive

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced the continuation of their collaboration with Zymeworks Inc.

The Milken Institute COVID-19 Treatment and Vaccine Tracker has identified more than 111 vaccines and 197 treatments in the pipeline to treat and prevent COVID-19.

Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 16,291,952 of the Company’s ordinary shares, at a purchase price of $0.30690 per share, in a registered direct offering.

AIDS Healthcare Foundation praised the work of U.S. Representatives Lloyd Doggett and Rosa DeLauro for their demand for an accounting of how Gilead Sciences has used public funds to make private profit off government research for the development of remdesivir.

Avadel Pharmaceuticals plc announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 11, 2020, to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2020.

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced plans to report first quarter 2020 financial results on Monday, May 11, 2020, before market open.

GenMark Diagnostics, Inc., a leading provider of automated, multiplex molecular diagnostic testing systems, announced financial results for the quarter ended March 31, 2020.

Insmed Incorporated announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

NuVasive, Inc. announced that management will present at the virtual BofA Securities 2020 Healthcare Conference on Tuesday, May 12 at 5:00 p.m. ET/2:00 p.m. PT.

Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the expected manufactur